<?xml version="1.0" encoding="UTF-8"?><xmi:XMI xmlns:cas="http:///uima/cas.ecore" xmlns:xmi="http://www.omg.org/XMI" xmlns:type="http:///org/apache/uima/trials/type.ecore" xmlns:tcas="http:///uima/tcas.ecore" xmi:version="2.0">
    <cas:NULL xmi:id="0"/>
    <tcas:DocumentAnnotation xmi:id="1" sofa="6" begin="0" end="1649" language="x-unspecified"/>
    <type:OSMean xmi:id="13" sofa="6" begin="686" end="696"/>
    <type:OSMean xmi:id="17" sofa="6" begin="719" end="729"/>
    <type:PFSMean xmi:id="21" sofa="6" begin="785" end="795"/>
    <type:PFSRate xmi:id="25" sofa="6" begin="819" end="829"/>
    <type:ORR xmi:id="29" sofa="6" begin="1010" end="1014"/>
    <type:ORR xmi:id="33" sofa="6" begin="1028" end="1032"/>
    <cas:Sofa xmi:id="6" sofaNum="1" sofaID="_InitialView" mimeType="text" sofaString="BACKGROUND: Prior to the 2008 advent of sorafenib, traditional cytotoxic agents&#13;&#10;were the therapeutic mainstay for patients with advanced hepatocellular carcinoma&#13;&#10;(HCC). We thus undertook a clinical study of sorafinib and conventional cytotoxic&#13;&#10;therapy for HCC, comparing efficacy and safety.&#13;&#10;METHODS: From January, 2002 to December, 2009, 173 patients with unresectable HCC&#13;&#10;were reviewed retrospectively. Among them, 44 (25.4%) had been treated with&#13;&#10;sorafenib, and the remainder had received cytotoxic therapy (CTX). We evaluated&#13;&#10;objective response rate (ORR), progression free survival (PFS), overall survival &#13;&#10;(OS), and toxicity profiles.&#13;&#10;RESULTS: Median OS of sorafinib was 23.0 weeks (95% CI, 8.1-37.9) vs 43.6 weeks&#13;&#10;(95% CI, 34.0-53.2) for CTX. Likewise, median PFS was 11.1 weeks (95% CI,&#13;&#10;6.5-15.8) vs 12.4 weeks (95% CI, 8.1-16.7) for sorafenib and CTX, respectively.&#13;&#10;Neither parameter differed significantly (OS, p?=?0.105; PFS, p?=?0.496). ORR and&#13;&#10;disease control rate for sorafenib were 2.3% and 52.3% vs 6.2% and 43.4% for CTX.&#13;&#10;CTX-treated patients experienced more Grade 3/4 neutropenia (19.7% vs 0% for&#13;&#10;sorafenib), while sorafenib therapy was more often linked to dermatologic&#13;&#10;toxicities (all grades), such as hand-foot skin reaction, rash, and pruritus.&#13;&#10;CONCLUSION: Although sorafenib has become the treatment of choice for advanced&#13;&#10;HCC, there are still unsettled issues regarding the optimal use of sorafenib. Our&#13;&#10;analysis indicates that conventional CTX can be another option of treatment for&#13;&#10;advanced HCC. To improve clinical outcomes, further prospective investigations&#13;&#10;which define the role of CTX are needed."/>
    <cas:View sofa="6" members="1 13 17 21 25 29 33"/>
</xmi:XMI>
